Moderna COVID Vaccine Still Has 'Best-In-Class Potential,' Says Barclays
August 06, 2020 at 09:30 AM EDT
Barclays analyst Gena Wang raised the firm's price target on Moderna to $84 from $68 and keeps an Overweight rating on the shares.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|